Phase II study of trastuzumab with modified docetaxel, cisplatin, and 5 fluorouracil in metastatic HER2-positive gastric cancer
ConclusionThe combination of mDCF and trastuzumab is effective and safe in patients with metastatic HER2-positive gastric or GE junction adenocarcinoma and can be considered as an option for selected patients. This trial is registered at ClinicalTrials.gov, number NCT00515411.
Source: Gastric Cancer - Category: Gastroenterology Source Type: research
More News: Adenocarcinoma | Cancer | Cancer & Oncology | Docetaxel | Gastric (Stomach) Cancer | Gastroenterology | HER2 | Herceptin | Study | Taxotere | Toxicology